George Scangos, Vir CEO (BIO via YouTube)

As GSK-part­nered Covid an­ti­body racks up glob­al sales, Vir ax­es WuXi deal and grabs back Chi­na rights

Ear­ly on in the Covid-19 pan­dem­ic, Vir Biotech­nol­o­gy en­list­ed Chi­na’s pow­er­house CD­MO WuXi Bi­o­log­ics for cell line de­vel­op­ment, process and for­mu­la­tion de­vel­op­ment as well as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.